Endocrinol Metab.  2015 Sep;30(3):318-325. 10.3803/EnM.2015.30.3.318.

Serum Concentrations of Ghrelin and Leptin according to Thyroid Hormone Condition, and Their Correlations with Insulin Resistance

Affiliations
  • 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea. chanh@schmc.ac.kr

Abstract

BACKGROUND
Thyroid hormones can influence energy metabolism and insulin sensitivity via their interaction with adipocytokines and gut hormones. The aims of this study were to evaluate differences in serum ghrelin and leptin concentrations according to thyroid hormone levels, and to investigate the correlation of insulin resistance.
METHODS
A total of 154 patients (57 hyperthyroid patients, 61 euthyroid patients, and 36 hypothyroid patients; mean age, 47.9 years) were enrolled. Serum leptin, ghrelin, and insulin levels were measured and insulin resistance was calculated using the formula of the homeostasis model assessment of insulin resistance (HOMA-IR).
RESULTS
There were no differences in mean concentrations of ghrelin or leptin among the three groups. There were no significant differences in insulin levels between the groups (P=0.06), although hyperthyroid patients had borderline statistically significantly higher levels of insulin than did euthyroid subjects by post hoc test (26.4 microIU/mL vs. 16.1 microIU/mL, P=0.057). Regarding HOMA-IR index, the mean levels were highest in the hyperthyroid group among those of the three groups (hyperthyroid vs. euthyroid vs. hypothyroid, 6.7 vs. 3.8 vs. 4.4, P=0.068). Plasma levels of ghrelin were significantly negatively correlated with age, insulin, glucose, body mass index (BMI), and HOMA-IR. Plasma levels of leptin showed significant positive correlation with BMI and triglyceride. There were no significant correlations among thyroid hormone, thyrotropin, ghrelin, leptin, or insulin.
CONCLUSION
The present study found that serum ghrelin, leptin, and insulin levels didn't differ according to thyroid function conditions. Further studies with larger numbers of patients are required to establish a direct relationship between plasma ghrelin, leptin, and thyroid hormone.

Keyword

Thyroid hormones; Ghrelin; Leptin; Insulin; Insulin resistance

MeSH Terms

Adipokines
Body Mass Index
Energy Metabolism
Ghrelin*
Glucose
Homeostasis
Humans
Insulin Resistance*
Insulin*
Leptin*
Plasma
Thyroid Gland*
Thyroid Hormones
Thyrotropin
Triglycerides
Adipokines
Ghrelin
Glucose
Insulin
Leptin
Thyroid Hormones
Thyrotropin

Reference

1. Silva JE. The thermogenic effect of thyroid hormone and its clinical implications. Ann Intern Med. 2003; 139:205–213.
2. Weetman AP. Graves' disease. N Engl J Med. 2000; 343:1236–1248.
3. Lambadiari V, Mitrou P, Maratou E, Raptis AE, Tountas N, Raptis SA, et al. Thyroid hormones are positively associated with insulin resistance early in the development of type 2 diabetes. Endocrine. 2011; 39:28–32.
4. Mueller A, Schofl C, Dittrich R, Cupisti S, Oppelt PG, Schild RL, et al. Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome. Hum Reprod. 2009; 24:2924–2930.
5. Dimitriadis G, Baker B, Marsh H, Mandarino L, Rizza R, Bergman R, et al. Effect of thyroid hormone excess on action, secretion, and metabolism of insulin in humans. Am J Physiol. 1985; 248(5 Pt 1):E593–E601.
6. Dimitriadis GD, Raptis SA. Thyroid hormone excess and glucose intolerance. Exp Clin Endocrinol Diabetes. 2001; 109:Suppl 2. S225–S239.
7. Chubb SA, Davis WA, Davis TM. Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study. J Clin Endocrinol Metab. 2005; 90:5317–5320.
8. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, et al. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab. 2006; 91:4930–4937.
9. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011; 11:85–97.
10. Aydogan BI, Sahin M. Adipocytokines in thyroid dysfunction. ISRN Inflamm. 2013; 2013:646271.
11. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011; 2011:439463.
12. Iglesias P, Alvarez Fidalgo P, Codoceo R, Diez JJ. Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function. Clin Endocrinol (Oxf). 2003; 59:621–629.
13. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50:1511–1525.
14. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev. 2007; 8:21–34.
15. Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Ghrelin: a hormone with multiple functions. Front Neuroendocrinol. 2004; 25:27–68.
16. Gimenez-Palop O, Gimenez-Perez G, Mauricio D, Berlanga E, Potau N, Vilardell C, et al. Circulating ghrelin in thyroid dysfunction is related to insulin resistance and not to hunger, food intake or anthropometric changes. Eur J Endocrinol. 2005; 153:73–79.
17. Braclik M, Marcisz C, Giebel S, Orzel A. Serum leptin and ghrelin levels in premenopausal women with stable body mass index during treatment of thyroid dysfunction. Thyroid. 2008; 18:545–550.
18. Fruhbeck G, Jebb SA, Prentice AM. Leptin: physiology and pathophysiology. Clin Physiol. 1998; 18:399–419.
19. Jung CH, Kim BY, Mok JO, Kang SK, Kim CH. Association between serum adipocytokine levels and microangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig. 2014; 5:333–339.
20. Wennlund A, Felig P, Hagenfeldt L, Wahren J. Hepatic glucose production and splanchnic glucose exchange in hyperthyroidism. J Clin Endocrinol Metab. 1986; 62:174–180.
21. Ingbar SH, Werner SC, Braverman LE. Chapter 46, Catecholamines and the sympathoadrenal system in thyrotoxicosis. Werner and Ingbar's the thyroid: a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven;1996. p. 661–670.
22. Harris PE, Walker M, Clark F, Home PD, Alberti KG. Forearm muscle metabolism in primary hypothyroidism. Eur J Clin Invest. 1993; 23:585–588.
23. Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009; 160:785–790.
24. Sinha RA, Singh BK, Yen PM. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. Trends Endocrinol Metab. 2014; 25:538–545.
25. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402:656–660.
26. Riis AL, Hansen TK, Moller N, Weeke J, Jorgensen JO. Hyperthyroidism is associated with suppressed circulating ghrelin levels. J Clin Endocrinol Metab. 2003; 88:853–857.
27. El Gawad SS, El Kenawy F, Mousa AA, Omar AA. Plasma levels of resistin and ghrelin before and after treatment in patients with hyperthyroidism. Endocr Pract. 2012; 18:376–381.
28. Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A. Plasma ghrelin concentrations are not regulated by glucose or insulin: a double-blind, placebo-controlled crossover clamp study. Diabetes. 2003; 52:16–20.
29. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab. 2001; 86:5083–5086.
30. Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010; 59:2145–2151.
31. Amini P, Wadden D, Cahill F, Randell E, Vasdev S, Chen X, et al. Serum acylated ghrelin is negatively correlated with the insulin resistance in the CODING study. PLoS One. 2012; 7:e45657.
32. Taylor AL, Finster JL, Mintz DH. Metabolic clearance and production rates of human growth hormone. J Clin Invest. 1969; 48:2349–2358.
33. Cooper DS, Ridgway EC, Kliman B, Kjellberg RN, Maloof F. Metabolic clearance and production rates of prolactin in man. J Clin Invest. 1979; 64:1669–1680.
34. Ingbar SH, Werner SC, Braverman LE. Chapter 44, The pituitary in thyrotoxicosis. Werner and Ingbar's the thyroid: a fundamental and clinical text. 7th ed. Philadelphia: Lippincott-Raven;1996. p. 653–655.
35. Gjedde S, Vestergaard ET, Gormsen LC, Riis AL, Rungby J, Moller N, et al. Serum ghrelin levels are increased in hypothyroid patients and become normalized by L-thyroxine treatment. J Clin Endocrinol Metab. 2008; 93:2277–2280.
36. Sadegholvad A, Afkhamizadeh M, Ranjbar-Omrani G. Serum ghrelin changes in thyroid dysfunction. Arch Iran Med. 2007; 10:168–170.
37. Tanda ML, Lombardi V, Genovesi M, Ultimieri F, Lai A, Gandolfo M, et al. Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction. J Endocrinol Invest. 2009; 32:74–78.
38. Menendez C, Baldelli R, Camina JP, Escudero B, Peino R, Dieguez C, et al. TSH stimulates leptin secretion by a direct effect on adipocytes. J Endocrinol. 2003; 176:7–12.
39. Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J. Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proc Natl Acad Sci U S A. 2004; 101:10434–10439.
40. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50:707–709.
41. Ikezaki A, Hosoda H, Ito K, Iwama S, Miura N, Matsuoka H, et al. Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes. 2002; 51:3408–3411.
Full Text Links
  • ENM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr